Yuhan expands global reach through strategic contracts
The pharmaceutical company reported that its overseas business grew 12.3% year-on-year in the first half of 2026.
The pharmaceutical maker Yuhan grew its overseas business 12.3% year-on-year during the first half of 2026. This growth was driven by the export of C-type hepatitis virus treatment raw materials and AIDS treatment raw materials. The company said it intends to accelerate the global entry of finished medicines and continue identifying strategic export projects.
Prescription drugs represent the largest portion of the company's revenue, accounting for 50.9% of total sales. Non-prescription drugs contributed 10.5%, while the healthcare business segment accounted for 9.7%. The overseas business segment made up 19.5% of the total.
In the research and development sector, the company established a dedicated New Modality organization within its research center. Yuhan is shifting toward R&D operations based on a portfolio perspective that considers disease areas, technology platforms, and development stages. The company also intends to expand open innovation through strategic collaborations with academic circles and bio-ventures.
Operational capacity varied across facilities during the period. The Ochang plant recorded a utilization rate of 98.2% for pharmaceuticals. Yuhan Chemical reported a 75.0% utilization rate for raw materials, and Wisemed recorded 74.4% for pharmaceuticals.
Regarding shareholder returns, the company is pursuing a policy to increase dividends. Yuhan said it aims to consider and implement dividend expansion based on increases in net income.
The company's market share reached 6.5% in 2025, up from 6.3% in 2024 and 6.1% in 2023. By the end of 2025, Yuhan held 1,104 total patents, consisting of 231 domestic and 873 overseas registrations.